Halifax Hospital Joins Breath Test Study to Detect Breast Cancer
The IWK Health Centre in Halifax has become the second Canadian site in a study led by New Brunswick-based Breathe BioMedical, investigating whether volatile organic compounds in breath samples can indicate breast cancer. The non-invasive test aims to supplement mammograms, particularly for women with dense breast tissue.
The IWK Health Centre in Halifax has become the second Canadian site to join a study investigating whether breast cancer can be detected through breath samples. The research is conducted in partnership with Breathe BioMedical, a research group based in New Brunswick.

Dr. Ashley Drohan, Dr. Gregory Knapp, and Dr. Zina Kellow are leading the study at the IWK Breast Health Research Unit. The goal is to determine if patterns in volatile organic compounds (VOCs) found in breath samples can indicate the presence of breast cancer. Participants provide three breath samples using individual cartridges containing absorbent tubes. These samples collected at IWK are then sent to a lab in Moncton for analysis.
Breathe BioMedical CEO Bill Dawes stated that the current study involves sites in Halifax and Moncton, aiming for approximately 800 participants. Eligible participants are women undergoing biopsies or MRIs at IWK. Reports on the specific age range for eligibility vary: SaltWire states ages 46 to 74, CBC reports ages 40 to 70, and CTV indicates ages 40 to 74.
A previous pilot study by Breathe BioMedical in Saint John demonstrated an 88 per cent overall accuracy rate using approximately 111 patients.

The breath test is intended to supplement, not replace, mammograms. It may help detect cancer earlier in women with dense breast tissue, a condition affecting 50 per cent of women. This research arrives as Nova Scotia currently has the highest breast cancer-specific mortality rate in Canada.